Drug intelligence / Profile preview

RMP-A03

Development stage: Phase 3
Lead developer: Suzhou Ruiming New Drug Research & Development
Modality: Small Molecules
Administration: Ophthalmic

Overview

RMP-A03 is a small molecule chemical drug developed for the treatment of pterygium, an ocular surface disease characterized by abnormal fibrovascular growth on the conjunctiva. The drug is being evaluated as an ocular suspension and has completed Phase 2 clinical trials assessing its safety and efficacy in patients with pterygium. The precise mechanism of action for RMP-A03 remains unknown, and it does not represent a novel mechanism of action. The developer and active organization behind this compound is Suzhou Ruiming New Drug Research & Development Co., Ltd., also referred to as Suzhou Raymon Pharmaceuticals Company, Ltd.[1][2][3]

Other names: nintedanib ophthalmic

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on RMP-A03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMP-A03.

Explore the full profile